Mr. Speaker, since 2017, guided by the Canadian drugs and substances strategy, CDSS, the Government of Canada has taken a comprehensive approach to address substance use issues and the overdose crisis, supported by over $1 billion in spending. There is no one-size-fits-all solution to prevent or reduce overdose deaths; a full range of services and supports are needed.
Safer supply sits within a continuum of services where medications are prescribed in the context of a therapeutic relationship between a health care provider and a patient. Safer supply services are informed by well-established domestic and international evidence from medication-assisted treatment, MAT, services, which are considered the gold standard of treatment for substance use disorder.
With regard to questions (a) and (b), surveillance conducted by the Public Health Agency of Canada, PHAC, on the overdose crisis shows a significant increase in apparent opioid-toxicity deaths in Canada beginning with the COVID-19 pandemic in 2020, and rates remain elevated today. PHAC also conducts forward modelling to provide estimates of how many opioid-related deaths may occur over the coming months in Canada. Projections are based on assumptions regarding the toxicity of the illegal drug supply and the impact of health interventions. The model considers all health interventions together and does not report projections for specific interventions, such as safer supply. The model is updated twice a year, in June and December.
Health Canada recognizes that additional high-quality evidence is needed that addresses potential benefits and risks of safer supply. To help build this evidence, Health Canada is supporting assessment and evaluation projects related to pilot projects funded by the substance use and addictions program, SUAP. This includes a preliminary assessment of 10 safer supply pilot projects in Ontario, British Columbia and New Brunswick.
The federal government, through the Canadian Institutes of Health Research, CIHR, is also supporting a study being conducted by a research team from the Canadian research initiative in substance misuse. This four-year evaluation research project focuses on program implementation and the short-term health outcomes of 11 of the government-funded safer supply pilot projects. The final results of this study are expected in 2025. Additionally, CIHR has awarded $2 million to the University of Victoria to support a four-year study evaluating the safer supply initiatives in British Columbia in partnership with indigenous leaders, elders and system partners.
With regard to questions (c) and (d), there is no one single intervention alone that will reduce overdose deaths and solve the overdose crisis. This crisis is being driven by a highly toxic illegal drug supply and a number of underlying socio-economic factors. This is why the federal government has taken a broad, comprehensive approach under the CDSS focusing on prevention, treatment, harm reduction and enforcement.
All SUAP-funded safer supply pilot projects are time-limited, innovative interventions designed to evaluate the effectiveness of providing pharmaceutical-grade medications as safer alternatives to the contaminated illegal drug supply in Canada. These pilot projects must have linkages to provincial and/or territorial health systems, involvement of people with lived and living experience of substance use in design and planning and prescriber or health care provider oversight, and must demonstrate commitments to research and evaluation.
Safer supply services exist in a limited number of locations in Canada, and currently serve a relatively small number of clients compared to the total number of people who use drugs and who are at risk of overdose due to the toxic illegal drug supply in Canada. At the federal level, there are 29 funded pilot projects, serving approximately 4,300 clients nationally. The focus of federally funded projects has been on building the evidence around this new practice.
Under the CDSS, the Government of Canada will continue to undertake a comprehensive and evidence-based approach to substance use issues and the overdose crisis, including testing new ideas and approaches to help save lives and reduce harms. We will continue to work with all levels of governments and key stakeholders, who also have critical roles to play. We will continue to monitor and assess all available evidence regarding our approach, including studying the outcomes of safer supply pilot projects, to inform both current and future actions and make adjustments, including implementing risk mitigation measures as appropriate.